Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  lenvatinib mesylate
Find trials that include:  Any drugs shown
Results 1-14 of 14 for your search:
Start Over
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: E7080-G000-307, NCI-2017-00073, NCT02811861
Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: E7080-A001-111, NCI-2016-00529, NCT02501096
Eribulin Mesylate and Lenvatinib Mesylate in Treating Patients with Stage IV Breast Cancer, Non-Small Cell Lung Cancer, or Sarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CTMS 15-2139, NCI-2016-00344, HSC20150891H, NCT02640508
Lenvatinib Mesylate in Treating Patients with Progressive, Recurrent, or Metastatic Adenoid Cystic Carcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15-327, NCI-2016-00825, NCT02780310
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E7080-M000-213, NCI-2016-01668, NCT02657369
Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ACCRU-ITOG-1504, NCI-2016-01752, NCT02973997
Lenvatinib in Treating Patients with Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC1575, NCI-2016-02032, NCT03008369
Lenvatinib Mesylate and Paclitaxel in Treating Patients with Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: OSU-15273, NCI-2016-00256, 2016C0009, NCT02788708
Capecitabine, Lenvatinib Mesylate, and External Beam Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer before Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18646, NCI-2016-01553, NCT02935309
Lenvatinib Mesylate and Capecitabine in Treating Patients with Advanced Cancers
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2016-0323, NCI-2016-01982, NCT02915172
An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: E7080-G000-398, NCI-2014-01802, NCT02211222
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients with Metastatic Endocrine Cancer
Status: Active
Phase: No phase specified
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2014-0864, NCI-2015-02058, NCT02592356
Start Over